Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of IC14 in Hospitalized Patients With Community-Acquired Pneumonia and Sepsis
NCT00042588Phase 2Completed
- Sponsor
- ICOS Corporation
- Start
- May 2002
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atibuclimab in community acquired pneumonia (CAP), sepsis, sponsored by ICOS Corporation. Started May 2002; status: completed.
02
Drugs
atibuclimab
03
Conditions
community acquired pneumonia (CAP)sepsis
Beyond the preview
Go deeper on NCT00042588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00042588.